13F Holdings
中文EN

VTVT vTv Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1641489 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY216,600.0%
TTM net income YoY67.3%
TTM EPS YoY—
Revenue 3-yr CAGR1,499.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-29.8%
Net margin-20.8%
FCF margin—
EBITDA margin-29.8%

Returns

ROE-11.0%
ROA-8.6%
ROIC (approx.)—
Asset turnover0.41x

Leverage & solvency

Liabilities / assets11.3%
Debt / equity0.00x
Current ratio11.19x
Interest coverage—

Cash quality & payout

Operating cash flow / net income2.83x
Accruals ratio15.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$1.02M$0$2.02M$4.00M
R&D expense$17.86M$11.55M$13.60M$12.36M$13.32M
SG&A expense$14.95M$13.65M$11.91M$12.20M$12.34M
Operating income-$32.81M-$24.18M-$25.50M-$22.54M-$21.66M
Interest expense—$0$13,000$15,000$12,000
Pretax income-$31.08M-$22.61M-$25.97M-$24.87M-$17.62M
Income tax$0$100,000$0$200,000$115,000
Net income-$26.97M-$18.46M-$20.25M-$19.16M-$12.99M
EBITDA-$32.79M-$24.09M-$25.41M-$22.45M-$21.57M
EPS (diluted)—————
Balance sheet
Cash & equivalents$88.93M$36.75M$9.45M$12.13M$13.41M
Receivables—$62,000$102,000$173,000$57,000
Current assets$89.89M$38.11M$10.66M$27.09M$15.62M
PP&E, net—$28,000$117,000$207,000$278,000
Total assets$89.90M$38.27M$11.02M$33.24M$25.47M
Current liabilities$6.64M$5.20M$10.62M$7.71M$8.50M
Short-term debt————$256,000
Total liabilities$25.46M$23.96M$29.57M$27.40M$10.25M
Shareholders' equity$64.44M$12.20M-$24.68M-$10.74M-$9.74M
Cash flow statement
Operating cash flow-$25.25M-$25.31M-$19.08M-$16.02M-$19.31M
Capital expenditure—$0$0$21,000$0
Free cash flow—-$25.31M-$19.08M-$16.04M-$19.31M
Investing cash flow$0$0$4.40M-$21,000$0
Financing cash flow$77.44M$52.61M$12.00M$14.75M$26.98M
Depreciation & amortization$16,000$89,000$90,000$92,000$89,000
Stock-based compensation$3.77M$2.76M$1.58M$1.27M$2.36M

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.